| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
| Company Name: |
BOC Sciences |
| Tel: |
16314854226 |
| Email: |
info@bocsci.com |
DV 7028 hydrochloride manufacturers
|
| | DV 7028 hydrochloride Basic information |
| Product Name: | DV 7028 hydrochloride | | Synonyms: | DV 7028 hydrochloride;3-[2-[4-(4-Fluorobenzoyl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2H-pyrido[1,2-a]-1,3,5-triazine-2,4(3H)-dione hydrochloride | | CAS: | 133364-62-2 | | MF: | C21H26ClFN4O3 | | MW: | 436.91 | | EINECS: | | | Product Categories: | | | Mol File: | 133364-62-2.mol |  |
| | DV 7028 hydrochloride Chemical Properties |
| storage temp. | Desiccate at RT | | solubility | Soluble to 10 mM in water with gentle warming and to 10 mM in DMSO with gentle warming | | form | Powder |
| | DV 7028 hydrochloride Usage And Synthesis |
| Description | Selective 5-HT2A receptor antagonist (Ki = 22 nM for at 5-HT2 receptors). Exhibits no affinity for 5-HT1A, 5-HT1B or 5-HT1D receptors. Inhibits collagen-induced serotonin secretion and platelet aggregation; displays no effect on serotonin uptake by platelets. Shown to inhibit arterial thrombus formation, but not venous thrombosis, in rat models. | | Uses | DV-7028 is a selective 5-hydroxytryptamine2 (5-HT2) receptor antagonist[1]. | | in vivo | DV-7028 (0.1 mg/kg, intravenously) reduced the frequency of cyclic flow reductions by 77% in dog and improved the nadir of coronary blood flow velocity that indicated the severity of cyclic flow reductions [1]. | | IC 50 | 5-HT2 Receptor | | References | [1] Tanaka T, et al. Combined effect of the 5-HT2 receptor antagonist DV-7028 and aspirin or heparin on coronary cyclic flow reductions in dogs. Cardiovasc Res. 1993 Jul;27(7):1374-9. DOI:10.1093/cvr/27.7.1374 |
| | DV 7028 hydrochloride Preparation Products And Raw materials |
|